Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? - Wikidata - wikimedia - TriplyDB

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

http://www.wikidata.org/entity/Q35201583

about

Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience Stroma targeting nuclear imaging and radiopharmaceuticals.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Sequelae and survivorship in patients treated with (131)I-MIBG therapy Primary carcinoid tumour of the kidney: a review of the literature.Yttrium-labelled peptides for therapy of NET.¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.Radiation exposure to caregivers from patients undergoing common radionuclide therapies: a review.Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Radionuclide Therapy for Neuroendocrine Tumors.Radiolabeled peptides: valuable tools for the detection and treatment of cancer Long-term results of PRRT in advanced bronchopulmonary carcinoid.The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors.Management of the hormonal syndrome of neuroendocrine tumors.THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience.Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.90Y/177Lu-DOTATATE therapy: survival of the fittest?A case of primary renal carcinoid tumor.Hindgut neuroendocrine neoplasms - characteristics and prognosis.Theranostics of Neuroendocrine Tumors.Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study.Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.Theranostics: radionuclide imaging and therapy in neuroendocrine tumours.Therapy: Neuroendocrine cancer--are two radionuclides better than one?MEDICINAL RADIOPHARMACEUTICAL CHEMISTRY OF METAL RADIOPHARMACEUTICALS ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

P2860

Q33403035-5954DD54-1D9E-4130-82F0-35CE3905C40A Q33961370-DE40FB6A-C380-47A7-BFC8-E6289A0A777A Q34157391-7BAD39C0-0D67-47E9-99BB-976E7219B942 Q34318792-1A446AEB-9704-472C-B8DB-DB61FDCB30FC Q35176280-EE9614E2-1E36-43C6-943C-9A729B10B1BA Q35917106-52D52360-628C-49D9-9593-F8D368902DBC Q35999606-22B8CBDF-4C7E-4DAD-965A-E2D3948639AE Q36755905-2E6943E1-6633-4C61-9866-B4E916CB01B5 Q37081870-FE211DD4-0E4D-4D6C-8B45-ED68ACDF5D81 Q37127276-3240A115-550F-47F0-9ABA-087783181806 Q37990401-A4861A39-95E2-4CF7-94F8-238CEA4172B0 Q37990403-B2C80695-710C-4FF7-ABFF-C3B14638D781 Q38054112-283AC123-E3E8-4F62-B702-07B125D12D8E Q38241463-A4C72816-51A7-4239-9C7E-D834B072D49F Q38271733-2C9C9C11-5BF3-410B-827F-717444E67460 Q38272267-B15A19EF-EB3D-4D73-BC2D-3D1E20E755AC Q38884776-D9D81BB2-8648-4109-9C5B-068741EC7592 Q38909078-DC30EF4F-1F35-4073-A44B-73C711456D32 Q39144880-8209632B-2BFF-4E9B-BBA0-001BC8CB6EA8 Q39596344-217A5DEE-52D9-4B28-9698-04277831C003 Q40516842-F0F008CA-ABC2-47F7-A415-545E671CF5AA Q40616326-DEAC0955-58F6-4CB4-AD25-BCE1BFE4D538 Q41832570-1DB7B78F-4582-4C55-AAE6-7B4FADDE42F5 Q42068740-0856C898-8192-4D65-BF25-A6B09DDCDDC3 Q42177470-0BB56DC8-09BF-4D1E-976A-27618D3D52B3 Q42345704-58FB4145-39F2-481D-BF43-2138931610B8 Q42548064-B7D6FE24-2230-4357-84DB-8C6F200D7C20 Q42836462-A10E014C-C406-460B-BD26-AA03716F733B Q42906685-408D3D5C-03F0-4D27-B763-812D45D20C71 Q43137642-FDE5B95D-9044-4A07-B88F-401434286A98 Q47104431-0FF86F13-8432-4C0E-86FB-D1998BCF75C5 Q49612068-3616FA49-8FB3-463D-A62E-04BE97236C6F Q50790805-01A370DF-6D79-4524-8422-64AECF6FBB83 Q53092330-6235C74E-806C-4447-A66F-2E8D25558597 Q54191380-5C47B46C-75A2-42A3-8D1C-9387AB0FE14A Q55056043-2E3B67A0-9359-4335-BBEB-09F439F25EB4 Q56619661-9A1A00B3-7829-4FF7-BC83-9BDB8318F97C Q57990732-84F15A11-C97A-4CC2-9600-90EE2B194FB5 Q58199982-296B3622-ED61-4AFE-994D-E7F41FADFC9A

P2860

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

http://www.wikidata.org/entity/Q35201583

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clinical results of radionucli ...... ch is a better therapy option?

@ast

Clinical results of radionucli ...... ch is a better therapy option?

@en

type

label

Clinical results of radionucli ...... ch is a better therapy option?

@ast

Clinical results of radionucli ...... ch is a better therapy option?

@en

prefLabel

Clinical results of radionucli ...... ch is a better therapy option?

@ast

Clinical results of radionucli ...... ch is a better therapy option?

@en

P1433

Q35201583-8B74DE86-0FD5-4DE6-BA47-1441CC13E936

P1476

Q35201583-46B625D0-7527-44C1-A6EB-0BF9AF28FD61

P2093

Q35201583-30A8E15D-EF54-4C4D-85BA-35616F89183F

Q35201583-4706088F-0415-4BB7-A1C2-BA354D9DA970

Q35201583-925FAD2F-D9ED-46A6-9C6D-E824CDEB8CB6

Q35201583-FA19E67C-6F9D-43A6-A771-4BE881E2BA00

P2860

Q35201583-0170619B-926F-487C-AE1E-9635FBD0BB69

Q35201583-0627BFA2-E41A-478E-97C6-587FEDAFA8E3

Q35201583-100EC44D-2EF7-445E-B18F-EB05D05A8982

Q35201583-16772A77-568C-4F81-BB65-F68E85DA9DEF

Q35201583-16D77A86-DE92-4341-99F3-EE9BF24B131A

Q35201583-22525ADD-416A-419B-853D-7CE4F552ADAA

Q35201583-26976456-FABA-4FCE-86C0-EF5B323AEE8A

Q35201583-30C0526F-CFCE-4129-9041-C3D62CD9DC7F

Q35201583-370A0B18-810E-4597-BC7E-1A484D188D3F

Q35201583-592F5AC2-822B-4BE3-B9E4-11E4ECF353AF

P2888

Q35201583-4FDAF799-6E75-492F-9A22-9C5087CE7462

P304

Q35201583-34F42310-9F91-4C8A-9454-815101C5C0C4

P31

Q35201583-B77E5F62-38D1-4EFB-8423-2046C3AA674B

P356

Q35201583-2F596DCF-FF8C-4C12-9EA8-D5AA1B41C3BC

P433

Q35201583-83D74331-32CD-4964-AE93-15FA448D0225

P478

Q35201583-5B618DFB-D673-4DD7-B81B-BFEE3D69C5D6

P50

Q35201583-6C98C4AB-82BE-4645-91D3-5AB3BD8AAAA9

Q35201583-DA689768-2B86-4764-AD65-FE2143F6F12F

P577

Q35201583-7D43D508-02A7-4661-89F6-D4217C3348AA

P5875

Q35201583-12547F7D-79D4-4A09-8E60-D41A13979236

P698

Q35201583-60DAF627-79C0-4E51-8DDA-434BC99ACCDE

P932

Q35201583-D0D73184-A3EE-4486-A034-35ABC513DEBE

P356

S00259-011-1833-X

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Clinical results of radionucli ...... ch is a better therapy option?

@en

P2093

Alicja Hubalewska-Dydejczyk

http://www.w3.org/2001/XMLSchema#string

Anna Sowa-Staszczak

http://www.w3.org/2001/XMLSchema#string

Dariusz Pawlak

http://www.w3.org/2001/XMLSchema#string

Renata Mikołajczak

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Peptide receptor imaging and therapy.

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors.

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations.

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

P2888

s00259-011-1833-x

P304

1788-1797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-011-1833-X

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Jolanta Kunikowska

Leszek Królicki

P577

2011-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51108364

http://www.w3.org/2001/XMLSchema#string

P698

21553086

http://www.w3.org/2001/XMLSchema#string

P932

3168754

http://www.w3.org/2001/XMLSchema#string